Traduction de «may to acquire » (Néerlandais → Français) :

TERMINOLOGIE

anomalie (granulatie)(granulocyt) of syndroom van | Alder | anomalie (granulatie)(granulocyt) of syndroom van | May-Hegglin | anomalie (granulatie)(granulocyt) of syndroom van | Pelger-Huët | hereditaire | leukocytaire | hypersegmentatie | hereditaire | leukocytaire | hyposegmentatie | hereditaire | leukomelanopathie
Anomalie (granulation) (granulocyte) ou syndrome de:Alder | May-Hegglin | Pelger-Huët | Hypersegmentation | Hyposegmentation | leucocytaire, héréditaire | Leucomélanopathie héréditaire

acquired immunodeficiency syndrome [AIDS] NNO | AIDS-related complex [ARC] NNO
Complexe relatif au SIDA [ARC] SAI Syndrome d'immunodéficience acquise [SIDA] SAI

CAP - community acquired pneumonie
pneumonie acquise dans la collectivité

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Vulnerable individuals may have the ability to handle this during many periods of their lives or even their entire lives thanks to the protective factors, which are either inherent or which they may have acquired during the events they have faced throughout their lives or thanks to the support of those close to them.
La personne vulnérable peut y faire face durant plusieurs périodes ou même toute sa vie grâce à des facteurs de protection, qui sont inhérents à la personne ou qui peuvent être acquis durant les événements de la vie qu’elle a vécus ou grâce au soutien de ses proches.

Sandoz agreed in May to acquire the generic oncology injectables business of EBEWE Pharma for EUR 925 million (USD 1.3 billion), which will create a new global growth platform and improve access to oncology medicines.
Sandoz a conclu un accord en mai en vue d’acquérir le secteur d’activité des génériques injectables d’EBEWE Pharma pour un montant d’EUR 925 millions (USD 1,3 milliard).

Sandoz – EBEWE Pharma On May 20, Novartis announced a definitive agreement for Sandoz to acquire the specialty generic injectables business of EBEWE Pharma for EUR 925 million (USD 1.3 billion) in cash, to be adjusted for any cash or debt assumed at closing.
Sandoz – EBEWE Pharma Le 20 mai, Novartis a annoncé avoir conclu un accord définitif portant sur l’acquisition par Sandoz du domaine thérapeutique des spécialités génériques injectables d’EBEWE Pharma pour EUR 925 millions (USD 1,3 milliard) en espèces, montant qui sera ajusté des liquidités ou des dettes estimées à la date de clôture.